Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYNTAX: CTLs and Vaccination Post-Transplant
NCT02843321Phase 1Unknown
- Sponsor
- University of Sydney
- Start
- Aug 2012
- Primary completion
- Dec 2017
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in cytomegalovirus infection (CMV), adenovirus infection, Epstein-Barr virus infection and 4 more, sponsored by University of Sydney. Primary endpoint: Safety of infection-specific T-cell infusion and vaccination at 1 week. Status: unknown.
02
Conditions
cytomegalovirus infection (CMV)adenovirus infectionEpstein-Barr virus infectionvaricella zoster virus infectioninfluenza
Beyond the preview
Go deeper on NCT02843321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02843321.